loader image
Friday, November 22, 2024
59.2 F
McAllen
We Welcome your Press Release
- Advertisement -

PREVENTION of COVID-19 in High-risk Subjects Using Long-acting Antibodies

Translate to Spanish or other 102 languages!

DHR Health Institute for Research and Development is initiating an innovative clinical study to prevent COVID-19 in high-risk patients. Image of illustration purposes.
DHR Health Institute for Research and Development is initiating an innovative clinical study to prevent COVID-19 in high-risk patients. Image of illustration purposes.

Mega Doctor News

- Advertisement -

Edinburg, TX – DHR Health Institute for Research and Development is initiating an innovative clinical study to prevent COVID-19 in high-risk patients.

This is the first such study that is designed to provide passive immunity to patients who have immunocompromised status and cannot mount a robust immune response when infected with the SARS-CoV-2 virus.

On December 8, 2021, the U.S. Food and Drug Administration issued an Emergency Use Authorization allowing the use of AstraZeneca’s long-acting antibody EVUSHELD to be used for prevention of COVID-19 in subjects 12 years and older with moderate to severe immunocompromised status before exposure to the virus.

- Advertisement -

“For various medical reasons, over seven million people in the United States remain vulnerable to moderate to severe infection with the SARS-CoV-2 virus” said Sohail Rao, MD, MA, DPhil, President & CEO, DHR Health Institute for Research & Development. “These are patients who are receiving chemotherapy for cancers, immunosuppressive drugs following transplantation and/or for conditions such as rheumatoid arthritis and lupus”.

“These patients despite vaccination, are unable to generate and sustain satisfactory immune response even after receiving booster doses of COVID-19 vaccine” said Rao “Treatment with this long-acting antibody will provide them with protection against SARS-CoV-2 virus for up to 6-9 months”.

If you or your patient is interested to participate in this study, please call 956-342-4896.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS McAllen’s Comprehensive Stroke Center Certified as Thrombectomy-Capable Stroke Center

Mega Doctor News Every 40 seconds, someone in the United States has...

What Are The Best Medicare Options For People Ages 65 And Over?

Medical News Today With so many options available, the best Medicare plans...

Vaping Linked to Heart Failure, Research Shows

Mega Doctor News CLEVELAND CLINIC – November 21st is the Great American Smokeout....

Addressing Nation’s Growing Drug Supply Shortages

Mega Doctor News ORLANDO, Florida — With drug shortages reaching the highest they...
- Advertisement -
×